• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Elaprase
    / Shire

    Active Ingredient
    Idursulfase 2 mg/ml

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    2 mg/ml

    partial basket chart 86190 5527

    Related information


    Elaprase is administered at a dose of 0.5 mg/kg body weight every week by
    intravenous infusion over a 3 hour period, which may be gradually reduced to 1 hour if no infusion-associated reactions are observed.
    Infusion of Elaprase at home may be considered for patients who have received
    several months of treatment in the clinic and who are tolerating their infusions well.
    Home infusions should be performed under the surveillance of a physician or other healthcare professional.
    Special populations
    Elderly patients: There is no clinical experience in patients over 65 years of age.
    Patients with renal or hepatic impairment: There is no clinical experience in patients with renal or hepatic insufficiency.
    Paediatric patients: The dose for children and adolescents is 0.5 mg/kg body weight weekly.
    Method of administration: For instructions on dilution of the medicinal product before administration see prescribing information.


    Long-term treatment of patients with Hunter Syndrome (Mucopolysaccharidosis II, MPS II).


    Severe or life-threatening hypersensitivity to the active substance or to any of the excipients if hypersensitivity is not controllable.

    Special Precautions

    See prescribing information for full details.

    Side Effects

    See prescribing information for full details.

    Shire Human Genetic Therapies, Inc.